Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PRME Prime Medicine Inc
- Stocks
- Healthcare
- NASDAQ: PRME
Price (delayed)
$1.27
Market cap
$166.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
$181.96M
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime
Highlights
PRME's revenue is up by 29% QoQ
PRME's gross profit is up by 29% from the previous quarter
PRME's debt has surged by 197% since the previous quarter and by 177% year-on-year
Prime Medicine's equity has plunged by 56% YoY and by 30% from the previous quarter
Key stats
What are the main financial stats of PRME
Market
Valuations
Earnings
Shares outstanding
131.29M
Market cap
$166.74M
Enterprise value
$181.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.56
Price to sales (P/S)
43.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.31
Revenue
$3.85M
Gross profit
$3.85M
Operating income
-$206.52M
Net income
-$202.01M
EBIT
-$202.15M
EBITDA
-$184.21M
Free cash flow
-$111.41M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$0.85
Book value per share
$0.82
Revenue per share
$0.03
TBVPS
$2.51
Total assets
$328.16M
Total liabilities
$221.24M
Debt
$121.15M
Equity
$106.92M
Working capital
$129.48M
Debt to equity
1.13
Current ratio
4.78
Quick ratio
4.62
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
-4,789.7%
Gross margin
100%
Net margin
-5,252.5%
Operating margin
-5,369.7%
Return on assets
-66.3%
Return on equity
-125.1%
Return on invested capital
-97.6%
Return on capital employed
-68.8%
Return on sales
-5,256%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRME stock price
How has the Prime Medicine stock price performed over time
Intraday
-5.22%
1 week
-4.51%
1 month
-4.51%
1 year
-80.22%
YTD
-56.51%
QTD
-36.18%
Financial performance
How have Prime Medicine's revenue and profit performed over time
Revenue
$3.85M
Gross profit
$3.85M
Operating income
-$206.52M
Net income
-$202.01M
Gross margin
100%
Net margin
-5,252.5%
PRME's net margin has surged by 85% year-on-year and by 20% since the previous quarter
The operating margin has surged by 85% year-on-year and by 21% since the previous quarter
PRME's revenue is up by 29% QoQ
PRME's gross profit is up by 29% from the previous quarter
Price vs fundamentals
How does PRME's price correlate with its fundamentals
Growth
What is Prime Medicine's growth rate over time
Valuation
What is Prime Medicine stock price valuation
P/E
N/A
P/B
1.56
P/S
43.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.31
The EPS has grown by 26% YoY and by 2.4% from the previous quarter
Prime Medicine's equity has plunged by 56% YoY and by 30% from the previous quarter
PRME's price to book (P/B) is 40% lower than its last 4 quarters average of 2.6
The P/S is 90% below the last 4 quarters average of 449.9
PRME's revenue is up by 29% QoQ
Efficiency
How efficient is Prime Medicine business performance
The ROS has soared by 85% YoY and by 20% from the previous quarter
The return on invested capital has grown by 26% year-on-year and by 7% since the previous quarter
The return on equity has declined by 25% since the previous quarter and by 24% year-on-year
Prime Medicine's return on assets has increased by 17% YoY
Dividends
What is PRME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRME.
Financial health
How did Prime Medicine financials performed over time
PRME's total assets is 48% greater than its total liabilities
The total liabilities has surged by 53% since the previous quarter
The quick ratio has decreased by 50% YoY and by 14% from the previous quarter
PRME's debt is 13% greater than its equity
PRME's debt has surged by 197% since the previous quarter and by 177% year-on-year
Prime Medicine's equity has plunged by 56% YoY and by 30% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.